Global Paroxysmal Supraventricular Tachycardia Market to Reach USD 521.88 Million by 2032 | CAGR of 6.7%

Category : Healthcare | Published Date : Jan 2025 | Type : Press Release

Paroxysmal Supraventricular Tachycardia Market Scope & Overview:

In the newly published report, Consegic Business Intelligence states that the Paroxysmal Supraventricular Tachycardia (PSVT) Market was valued at USD 310.65 million in 2024 and is projected to grow at a CAGR of 6.7%, reaching USD 521.88 million by 2032. PSVT is characterized by sudden, rapid heartbeats originating above the heart's ventricles. The market includes treatments such as antiarrhythmic drugs, catheter-based ablation procedures, and wearable monitoring devices for real-time diagnosis and management.

The report comprises the Paroxysmal Supraventricular Tachycardia Market Share, Size & Industry Analysis, based on Type (Atrioventricular Nodal Reentrant Tachycardia (AVNRT), Atrioventricular Reciprocating Tachycardia (AVRT), Atrial Tachycardia), Diagnosis (Electrocardiogram (ECG), Holter Monitoring, Event Monitoring, Electrophysiology (EP) Testing, Echocardiogram), Treatment (Medications, Vagal Maneuvers, Catheter Ablation, Electrical Cardioversion, Implantable Devices), End-User (Hospitals, Cardiology Clinics, Ambulatory Surgical Centers, Homecare Settings), and Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2025-2032.

The report contains detailed information on Paroxysmal Supraventricular Tachycardia Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profiles, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.

The rising prevalence of cardiovascular disorders and lifestyle-related risk factors are major drivers for the PSVT market. Additionally, advancements in remote monitoring and wearable cardiac devices present significant opportunities for early detection and management of PSVT.

Segmental Analysis :

Based on type, the market is segmented into Atrioventricular Nodal Reentrant Tachycardia (AVNRT), Atrioventricular Reciprocating Tachycardia (AVRT), and Atrial Tachycardia.

  • Atrioventricular Nodal Reentrant Tachycardia (AVNRT) dominated the market in 2024 due to its high prevalence and advancements in diagnostic and treatment solutions, including catheter ablation procedures.
  • Atrial Tachycardia is projected to grow at the fastest CAGR, driven by increasing cases among patients with structural heart diseases and advancements in personalized treatment options.

Based on diagnosis, the market is segmented into Electrocardiogram (ECG), Holter Monitoring, Event Monitoring, Electrophysiology (EP) Testing, and Echocardiogram.

  • Electrocardiogram (ECG) accounted for the largest market share in 2024 due to its affordability, simplicity, and high accuracy in detecting abnormal heart rhythms.
  • Electrophysiology (EP) Testing is expected to grow rapidly, supported by advancements in 3D mapping technologies and increasing availability of specialized electrophysiology labs.

Based on treatment, the market is segmented into Medications, Vagal Maneuvers, Catheter Ablation, Electrical Cardioversion, and Implantable Devices.

  • Catheter Ablation led the market in 2024 due to its high success rate in treating PSVT and minimal recurrence.
  • Medications are projected to grow at the fastest CAGR due to the rising prevalence of PSVT and increased adoption of antiarrhythmic drugs.

Based on end-user, the market is segmented into Hospitals, Cardiology Clinics, Ambulatory Surgical Centers, and Homecare Settings.

  • Hospitals accounted for the largest share of 48.65% in 2024, driven by comprehensive diagnostic, treatment, and post-operative care for PSVT patients.
  • Cardiology Clinics are expected to grow rapidly due to the rising demand for specialized outpatient care and the availability of advanced diagnostic tools.

Based on regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

  • North America dominated the market in 2024, valued at USD 103.05 million, driven by advanced healthcare infrastructure and high awareness of cardiac arrhythmias.
  • Asia-Pacific is projected to grow at the fastest CAGR of 7.1%, fueled by rising cardiovascular conditions and improving healthcare infrastructure in China, India, and Japan.
Report Attributes Report Details
Study Timeline 2019-2032
Market Size in 2032 USD 521.88 Million
CAGR (2025-2032) 6.7%
Type Atrioventricular Nodal Reentrant Tachycardia (AVNRT), Atrioventricular Reciprocating Tachycardia (AVRT), Atrial Tachycardia
Diagnosis Electrocardiogram (ECG), Holter Monitoring, Event Monitoring, Electrophysiology (EP) Testing, Echocardiogram
Treatment Medications, Vagal Maneuvers, Catheter Ablation, Electrical Cardioversion, Implantable Devices
End-User Hospitals, Cardiology Clinics, Ambulatory Surgical Centers, Homecare Settings
By Region North America(U.S., Canada, Mexico)
Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe)
APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific)
Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA)
LATAM(Brazil, Argentina, Chile, Rest of LATAM)

Top Key Players & Competitive Landscape :

The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.

List of prominent players in the Paroxysmal Supraventricular Tachycardia Industry:

  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
  • Sanofi S.A. (France)
  • Johnson & Johnson (United States)
  • Bristol Myers Squibb (United States)
  • Medtronic plc (Ireland)
  • Abbott Laboratories (United States)
  • Boston Scientific Corporation (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • AstraZeneca plc (United Kingdom)

Recent Industry Developments :

  • July 2023: Milestone Pharmaceuticals reported positive results from the RAPID Phase 3 trial, evaluating etripamil nasal spray for the acute termination of PSVT, showing its potential as a self-administered treatment.
  • March 2023: Boston Scientific Corporation expanded its product portfolio by introducing an advanced catheter ablation system designed for minimally invasive treatment of PSVT.
  • January 2023: Medtronic plc partnered with leading hospitals to integrate AI-based monitoring systems for real-time detection of arrhythmias in PSVT patients.